secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059338
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma shareholders elect three Class I directors, ratify EY, approve say-on-pay
--------------------------------------------------------------------------------

- Elected Eran Broshy, James Kelly, Laurie Smaldone Alsup as Class I directors for three-year terms; votes for each exceeded 35 million.
- Ratified Ernst & Young as independent auditor for FY 2024 with 39,257,982 for, 228,078 against.
- Non-binding advisory resolution on named executive officer compensation passed with 35,205,714 for, 332,345 against.
- Total shares voted at annual meeting: 39,493,689 (81.3% of outstanding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/tm2413991d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer